These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 18547687)
1. Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori. Skene CD; Doidge C; Sutton P Vaccine; 2008 Jul; 26(31):3880-4. PubMed ID: 18547687 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background. Sutton P; Doidge C; Pinczower G; Wilson J; Harbour S; Swierczak A; Lee A FEMS Immunol Med Microbiol; 2007 Jul; 50(2):213-9. PubMed ID: 17567282 [TBL] [Abstract][Full Text] [Related]
3. Systemic immunization with unadjuvanted whole Helicobacter pylori protects mice against heterologous challenge. Harbour SN; Every AL; Edwards S; Sutton P Helicobacter; 2008 Dec; 13(6):494-9. PubMed ID: 19166414 [TBL] [Abstract][Full Text] [Related]
4. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Akhiani AA; Stensson A; Schön K; Lycke N Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008 [TBL] [Abstract][Full Text] [Related]
5. Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens. Vujanic A; Wee JL; Snibson KJ; Edwards S; Pearse M; Quinn C; Moloney M; Taylor S; Scheerlinck JP; Sutton P Vaccine; 2010 Mar; 28(14):2593-7. PubMed ID: 20096391 [TBL] [Abstract][Full Text] [Related]
6. Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection. Shi T; Liu WZ; Gao F; Shi GY; Xiao SD Helicobacter; 2005 Feb; 10(1):71-9. PubMed ID: 15691317 [TBL] [Abstract][Full Text] [Related]
8. ISCOMATRIX adjuvant for antigen delivery. Pearse MJ; Drane D Adv Drug Deliv Rev; 2005 Jan; 57(3):465-74. PubMed ID: 15560952 [TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of a DNA vaccine based on Helicobacter pylori urease B: failure to prevent experimental infection in the mouse model. Zavala-Spinetti L; Breslin MB; Correa H; Bégué RE Helicobacter; 2006 Dec; 11(6):517-22. PubMed ID: 17083372 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cells prevent rather than promote immunity conferred by a helicobacter vaccine using a mycobacterial adjuvant. Hitzler I; Oertli M; Becher B; Agger EM; Müller A Gastroenterology; 2011 Jul; 141(1):186-96, 196.e1. PubMed ID: 21569773 [TBL] [Abstract][Full Text] [Related]
11. ISCOMs and ISCOMATRIX. Sun HX; Xie Y; Ye YP Vaccine; 2009 Jul; 27(33):4388-401. PubMed ID: 19450632 [TBL] [Abstract][Full Text] [Related]
12. Oral vaccination against Helicobacter pylori with recombinant cholera toxin B-subunit. Kubota E; Joh T; Tanida S; Sasaki M; Kataoka H; Watanabe K; Itoh K; Oshima T; Ogasawara N; Togawa S; Wada T; Yamada T; Mori Y; Fujita F; Shimura T; Ohara H; Isaka M; Yasuda Y; Itoh M Helicobacter; 2005 Aug; 10(4):345-52. PubMed ID: 16104951 [TBL] [Abstract][Full Text] [Related]
13. Transcutaneous immunization with novel lipid-based adjuvants induces protection against gastric Helicobacter pylori infection. Hickey DK; Aldwell FE; Tan ZY; Bao S; Beagley KW Vaccine; 2009 Nov; 27(50):6983-90. PubMed ID: 19800441 [TBL] [Abstract][Full Text] [Related]
14. Oral immunization with recombinant Lactococcus lactis delivering a multi-epitope antigen CTB-UE attenuates Helicobacter pylori infection in mice. Li X; Xing Y; Guo L; Lv X; Song H; Xi T Pathog Dis; 2014 Oct; 72(1):78-86. PubMed ID: 24687988 [TBL] [Abstract][Full Text] [Related]
15. Heat shock protein complex vaccination induces protection against Helicobacter pylori without exogenous adjuvant. Chionh YT; Arulmuruganar A; Venditti E; Ng GZ; Han JX; Entwisle C; Ang CS; Colaco CA; McNulty S; Sutton P Vaccine; 2014 Apr; 32(20):2350-8. PubMed ID: 24625340 [TBL] [Abstract][Full Text] [Related]
16. Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Sanders MT; Deliyannis G; Pearse MJ; McNamara MK; Brown LE Vaccine; 2009 Apr; 27(18):2475-82. PubMed ID: 19368789 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity characterization of the multi-epitope vaccine CTB-UE with chitosan-CpG as combination adjuvants against Helicobacter pylori. Xing Y; Liu W; Li X; Guo L; Lv X; Xi T Biochem Biophys Res Commun; 2015 Jul; 462(3):269-74. PubMed ID: 25957472 [TBL] [Abstract][Full Text] [Related]
18. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Drane D; Gittleson C; Boyle J; Maraskovsky E Expert Rev Vaccines; 2007 Oct; 6(5):761-72. PubMed ID: 17931156 [TBL] [Abstract][Full Text] [Related]
19. Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses. Nyström J; Svennerholm AM Vaccine; 2007 Mar; 25(14):2591-8. PubMed ID: 17239498 [TBL] [Abstract][Full Text] [Related]
20. Recombinant Mycobacterium smegmatis mc(2)155 vaccine expressing outer membrane protein 26 kDa antigen affords therapeutic protection against Helicobacter pylori infection. Lü L; Cao HD; Zeng HQ; Wang PL; Wang LJ; Liu SN; Xiang TX Vaccine; 2009 Feb; 27(7):972-8. PubMed ID: 19111590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]